Cost of Non-Persistence with Oral Bisphosphonates in Osteoporosis Treatment in France
Author Information
Author(s): Cotté François-Emery, De Pouvourville Gérard
Primary Institution: CERMES, IFR69, INSERM U750, National Institute of Health and Medical Research, Villejuif, France
Hypothesis
What is the economic impact of non-persistence with bisphosphonates in post-menopausal osteoporosis treatment?
Conclusion
Improving persistence with oral bisphosphonates should lead to significant cost savings for the French healthcare system.
Supporting Evidence
- Each ten percentage point of persistence gain amounted to €58 per patient.
- The global annual cost of non-persistence was estimated to be over €30 million.
- Mean costs of 10-year management of fracture were significantly different between treatment alternatives.
Takeaway
If people take their osteoporosis medicine regularly, it can save a lot of money and help them avoid fractures.
Methodology
A Markov model was used to analyze the economic impact of non-persistence with bisphosphonates over a 10-year period.
Potential Biases
Potential biases in the data sources and assumptions made in the model.
Limitations
The model may underestimate costs as it does not account for all potential healthcare resource utilizations.
Participant Demographics
Women with post-menopausal osteoporosis in France.
Statistical Information
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website